Oral semaglutide does not slow the progression of Alzheimer's disease, according to a trial Oral semaglutide is not effective in slowing the progression of the disease in patients with mild Alzheimers disease, according to the findings of the first large-scale, randomised phase 3 clinical trials published in The Lancet
During perimenopause, hormonal changes can lead to weight gain, belly fat, cravings, and slow metabolism
Early and mid-stage trial results can provide useful signals, but they are not the same as long-term post-approval safety data
The SmPC notes an interaction with increased thyroxine exposure, so discuss the optimal timing of both medications with your GP, as they may need to be spaced further apart and thyroid function monitoring may be required
Other medical conditions are present, such as sleep apnea, severe arthritis, and even depression